Aura Biosciences (AURA) catalysts

Upcoming FDA decisions and readouts we track for Aura Biosciences, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 11 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Aura Biosciences (AURA, listed on Nasdaq). It concerns Belzupacap sarotalocan (bel-sar) (Early-stage choroidal melanoma).

First on the list: the Phase 3 readout for Belzupacap sarotalocan (bel-sar) (Early-stage choroidal melanoma), guided by the company to H2 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.

Background reading: How to read a Phase 3 topline readout.

Ticker: AURA
Next catalyst: H2 2027
Type: Phase 3 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Aura Biosciences AURA · Nasdaq	Belzupacap sarotalocan (bel-sar)	Early-stage choroidal melanoma	H2 2027 company guidance	Phase 3 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "Topline data from the 15-month primary endpoint remain on track for the second half of 2027." Source: 8-K exhibit 99.1, filed 11 Aug 2026 · verified 11 Sep 2026

Companies working on related conditions

CytomX Therapeutics (CTMX)Metastatic colorectal cancer (EpCAM ADC); Metastatic colorectal cancer; Advanced melanoma (masked interferon alpha-2b)
Eikon Therapeutics (EIKN)Non-squamous NSCLC (TLR7/8 agonist); Melanoma — first interim analysis; Advanced solid tumours (PARP1-selective); Advanced solid tumours (WRN helicase inhibitor